Journal Guides7 min readUpdated Mar 25, 2026

Nature Biotechnology SJR and Scopus Metrics: What the Numbers Actually Tell Authors

Nature Biotechnology's Scopus profile is extraordinary across biotech, molecular medicine, and bioengineering. The useful question is whether your paper is really technology-first enough for the journal.

Senior Researcher, Oncology & Cell Biology

Author context

Specializes in manuscript preparation and peer review strategy for oncology and cell biology, with deep experience evaluating submissions to Nature Medicine, JCO, Cancer Cell, and Cell-family journals.

Next step

Choose the next useful decision step first.

Use the guide or checklist that matches this page's intent before you ask for a manuscript-level diagnostic.

Open Journal Fit ChecklistAnthropic Privacy Partner. Zero-retention manuscript processing.Run Free Readiness Scan

Quick answer: Nature Biotechnology has one of the strongest Scopus profiles in the biotechnology ecosystem. Current Scopus-linked browser data reports a 2024 SJR of 19.006, a CiteScore of 58.8, and top-ranked or near-top-ranked positions across multiple biotechnology-related categories. That confirms exceptional prestige, but the submission decision still depends on whether the paper is really a platform or enabling-technology story rather than simply a strong biology paper with a technical angle.

The core metric picture

Metric
2024 value
What it tells you
SJR
19.006
Prestige-weighted influence is exceptional
CiteScore
58.8
Four-year citation performance is elite
SNIP
6.431
Field-normalized impact is also extremely strong
Quartile
Q1
The journal remains top-tier across Scopus classification
Category ranks
1 / 314, 1 / 177, 1 / 128, 2 / 323, 2 / 163
The journal leads or nearly leads several adjacent categories
JCR context
Impact factor 41.7
Web of Science tells the same flagship story

The useful reading is that Nature Biotechnology is not narrowly influential in one category. Its authority travels across biotechnology, engineering, translational science, and molecular medicine.

What the metrics actually help with

They help explain what kind of journal this is:

  • stronger for technologies, platforms, and enabling methods than for purely mechanistic biology
  • unusually powerful across several adjacent fields, not just one subject lane
  • capable of carrying real translational and biotech signal beyond academia

That is useful when the shortlist includes Nature Biotechnology, Nature Medicine, Nature Methods, or a strong specialist technology journal.

What the metrics do not answer

They do not tell you:

  • whether the technology is the real story
  • whether the benchmarking is strong enough
  • whether the adoption case is obvious enough
  • whether the paper is actually better framed for Nature Medicine or a biology-first venue

Those are still the fit questions that decide the outcome.

Why the profile matters for authors

At this SJR level, Nature Biotechnology can be extremely selective about manuscript identity. The journal's profile reflects a specific editorial product:

  • technology with obvious utility
  • credible benchmarks
  • broad adoption potential
  • consequence that travels beyond one narrow use case

That is why the numbers are useful. They show the journal has enough real authority that it does not need to indulge papers that are still mostly biology stories wearing platform language.

What should drive the submission decision instead

The better question is whether the manuscript is truly a Nature Biotechnology paper.

That is why the better next reads are:

If the paper is mainly translational medicine, mostly mechanistic biology, or too narrow in utility, the metrics do not rescue the mismatch. They only explain why the journal can reject many technically strong submissions quickly.

Practical verdict

Nature Biotechnology has a genuine flagship Scopus profile. That makes it a powerful target when the manuscript is technology-first, benchmarked convincingly, and useful beyond one narrow corner of the field.

But the author takeaway should still be about fit, not badge value. If the paper is really a platform or enabling-technology story, the upside is enormous. If it is still mostly a biology paper with a technical wrapper, the metric is already warning you. A free Manusights scan is the fastest way to pressure-test that before submission.

  1. Is Nature Biotechnology a good journal?, Manusights.
References

Sources

  1. 1. Nature Biotechnology journal browser entry, Wageningen University journal browser.
  2. 2. Nature Biotechnology journal page, Nature Portfolio.

Reference library

Use the core publishing datasets alongside this guide

This article answers one part of the publishing decision. The reference library covers the recurring questions that usually come next: how selective journals are, how long review takes, and what the submission requirements look like across journals.

Open the reference library

Before you upload

Choose the next useful decision step first.

Move from this article into the next decision-support step. The scan works best once the journal and submission plan are clearer.

Use the scan once the manuscript and target journal are concrete enough to evaluate.

Anthropic Privacy Partner. Zero-retention manuscript processing.

Internal navigation

Where to go next

Open Journal Fit Checklist